Introduction: Onychomadesis occurs when the nail plate separates from the nail matrix and nail bed, eventually leading to shedding of the nail. This condition has been attributed to viral infections, autoimmune disorders, drug side effects, and physical trauma. A subset of patients has a recurrent form of onychomadesis without a clear trigger; this phenomenon is not well characterized in the literature. Case Presentation: We present a case series of pediatric and adult patients with recurrent toenail onychomadesis in order to better characterize the disorder and explore possible etiologies, risk factors, and treatments. Discussion/Conclusion: For the cases herein, we propose microtrauma associated with footwear as the underlying etiology given the periodicity of nail shedding, exclusion of other etiological factors, and presence of predisposing risk factors in certain patients. Many patients saw improvement with application of urea 40% cream, suggesting this can be a valuable part of a treatment strategy, in addition to minimizing injury to involved digits.

Established Facts

  • Onychomadesis has been attributed to viral infections, autoimmune disorders, drug side effects, and physical trauma.

  • A subset of patients has a recurrent form of onychomadesis without a clear trigger.

Novel Insights

  • Certain cases of recurrent onychomadesis with no previously identified etiology may be due to microtrauma.

  • Urea 40% cream is a helpful treatment.

Onychomadesis is proximal separation of the nail plate from the nail matrix and nail bed. It is a severe form of Beau’s lines, which result from interruptions in nail matrix cell proliferation due to trauma or illness [1]. Onychomadesis has been attributed to viral infections (particularly coxsackieviruses), autoimmune disorders, drug side effects, and physical trauma, but some cases have no known etiology [2-5]. Involvement of the toenails may be more prevalent in athletes, particularly runners [5].

A subset of patients has a recurrent form of onychomadesis without a clear trigger [6]. These nail changes can be distressing for patients and/or guardians. Information about treatment, natural history, and detailed risk factors is lacking in the literature. To fill this gap, we reviewed our known cases of recurrent onychomadesis.

This work was conducted at Washington University School of Medicine in St. Louis, St. Louis, MO, USA, and the University of Bologna, Bologna, Italy. The Institutional Review Board of Washington University School of Medicine (St. Louis, MO, USA) and the Ethics Committee of the University of Bologna (Bologna, Italy) approved this retrospective case series. Data were gathered via chart abstraction. Cases of onychomadesis were considered recurrent if they had multiple layers of nails separated proximally from the nail bed. Herein, we present 11 pediatric (ages <18 years) and 40 adult patients with recurrent onychomadesis of the toenails (data in Table 1).

Table 1.

Demographic and clinical characteristics of patients with recurrent onychomadesis

Demographic and clinical characteristics of patients with recurrent onychomadesis
Demographic and clinical characteristics of patients with recurrent onychomadesis

All patients had involvement of the great toes, which in all cases were their longest toes. Morphology was remarkably similar – multilayered onychomadesis caused thickening of the affected nails, with moderate (shown in Fig. 1a) or marked (shown in Fig. 1b) hyperkeratosis. Forty-four (86%) patients had bilateral involvement. Two patients had involvement of the second toes (shown in Fig. 1a), in addition to the great toes. No patients had fingernail involvement. Twenty-seven (53%) patients participated in active hobbies or sports. Four patients (8%, all children) had anatomic anomalies of the feet, 3 with congenital malalignment of the great toes and one with pes planus. Two children had neuromuscular and neurological diagnoses.

Fig. 1.

Layering of nails with moderate thickness of the R1 and R2 toes of a child (a) and marked hyperkeratosis of the L1 toenail of a child (b).

Fig. 1.

Layering of nails with moderate thickness of the R1 and R2 toes of a child (a) and marked hyperkeratosis of the L1 toenail of a child (b).

Close modal

Urea cream (20–40%, 44/47 using 40%) was the primary treatment. Urea 40% cream produced improvement in 32/44 (73%) patients. One patient had improvement after bilateral great toenail avulsion, but the nails did not completely normalize. No patient had recent history of viral infection, documentation of an autoimmune diagnosis, nor known potential causative medications, making infectious, autoimmune, and drug triggers less likely.

For this series of 51 patients with recurrent onychomadesis of the toenails, we propose microtrauma associated with footwear as the underlying cause as all cases had involvement of the longest toe(s). Notably, many patients participated in active hobbies or sports, including running. Four cases had anatomic abnormalities of the feet, which may further support a traumatic etiology. The lateral deviation of nails in congenital malalignment of the great toenails (seen in 3 cases) can predispose these patients to microtrauma [7]. Many patients saw improvement with application of urea 40% cream, which promotes softening, enables trimming, and facilitates chemical avulsion when desired [8].

One pediatric patient had dystrophic nails since birth. There are reports of a rare genetic form of onychomadesis, including one of a mother and daughter with the condition [9]. In our case, no other family members had the condition. This study is limited by its retrospective nature. Some data points, including anatomic abnormalities and involvement in sports, may not have been documented in patient charts.

Recurrent onychomadesis may be underrecognized. This series illustrates the spectrum of clinical findings in this condition, from thin layering to marked hyperkeratosis. Due to the periodicity of nail shedding and exclusion of other possible etiological factors, the cases herein were most likely trauma induced. The cornerstone of treatment is to minimize injury to affected digits. Urea 40% cream can be part of this strategy, as it can make the nail smoother and more resistant to trauma.

This study protocol was reviewed and approved by the Institutional Review Board of Washington University School of Medicine (St. Louis, MO, USA) and the Ethics Committee of the University of Bologna (Bologna, Italy). Institutional Review Board ID number: 201911013. No identifiable photos or data are included, and therefore consent was not necessary. The study approval included the waiver of the need for written informed consent from the patients to publish the case series and any accompanying images.

The authors declare no conflicts of interest.

No funding was received for this manuscript.

Dana Sous contributed to design of the work, acquisition and interpretation of data, drafting of the manuscript, and coordination of revisions. Michela V.R. Starace contributed to acquisition and interpretation of data and critical revision of the manuscript. Lu Chen, Elizabeth L. Nieman, Milan J. Anadkat, and Bianca Maria Piraccini contributed to interpretation of data and critical revision of the manuscript. Carrie C. Coughlin contributed to design of the work, acquisition and interpretation of data, and critical revision of the manuscript. All authors approved the final version of the manuscript and agree to be accountable for the work.

The data that support the findings of this study are not publicly available due to the potential for patient identification in this case series, but are available in aggregate from the corresponding author (C.C.C.).

1.
Braswell
MA
,
Daniel
CR
 3rd
,
Brodell
RT
.
Beau lines, onychomadesis, and retronychia: a unifying hypothesis
.
J Am Acad Dermatol
.
2015 Nov
;
73
(
5
):
849
55
. Epub 2015 Oct 18. .
2.
Hardin
J
,
Haber
RM
.
Onychomadesis: literature review
.
Br J Dermatol
.
2015 Mar
;
172
(
3
):
592
6
. Epub 2014 Aug 19. .
3.
Ventarola
D
,
Bordone
L
,
Silverberg
N
.
Update on hand-foot-and-mouth disease
.
Clin Dermatol
.
2015 May–Jun
;
33
(
3
):
340
6
. Epub 2015 Apr 19. .
4.
Habibi
M
,
Mortazavi
H
,
Shadianloo
S
,
Balighi
K
,
Ghodsi
SZ
,
Daneshpazhooh
M
,
Nail changes in pemphigus vulgaris
.
Int J Dermatol
.
2008 Nov
;
47
(
11
):
1141
4
. Epub 2008 Nov 7. .
5.
Purim
KS
,
Leite
N
.
Sports-related dermatoses among road runners in Southern Brazil
.
An Bras Dermatol
.
2014 Jul–Aug
;
89
(
4
):
587
92
. Epub 2014 Jul 24. .
6.
Suchonwanit
P
,
Nitayavardhana
S
.
Idiopathic sporadic onychomadesis of toenails
.
Case Rep Dermatol Med
.
2016
;
2016
:
6451327
. Epub 2016 Jul 21. .
7.
Decker
A
,
Scher
RK
,
Avarbock
A
.
Acquired congenital malalignment of the great toenails
.
Skin Appendage Disord
.
2016 Feb
;
1
(
3
):
147
9
. Epub 2016 May 14. .
8.
Starace
M
,
Alessandrini
A
,
Piraccini
BM
.
Clinical evidences of urea at high concentration on skin and annexes
.
Int J Clin Pract
.
2020 Dec
;
74
(
Suppl 187
):
e13740
. Epub 2020 Nov 30. .
9.
Mehra
A
,
Murphy
RJ
,
Wilson
BB
.
Idiopathic familial onychomadesis
.
J Am Acad Dermatol
.
2000 Aug
;
43
(
2 Pt 2
):
349
50
. Epub 2000 Jul 20. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.